ADVERTISEMENT

Big pharma, big data: Why drugmakers want your health records


The ability to capture the experience of real-world patients, who represent a wider sample of society than the relatively narrow selection enrolled into traditional trials, is increasingly useful as medicine becomes more personalised. — Reuters

The ability to capture the experience of real-world patients, who represent a wider sample of society than the relatively narrow selection enrolled into traditional trials, is increasingly useful as medicine becomes more personalised. — Reuters

LONDON: Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world. 

Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs – something Roche aims to leverage, for example, with last month's US$2bil (RM7.81bil) purchase of Flatiron Health. 

   

ADVERTISEMENT